FDA Approves Wearable TTFields Therapy for Locally Advanced Pancreatic Cancer
TL;DR Summary
The FDA approved Optune Pax, a wearable device delivering abdominal tumor treating fields (TTFields) to treat locally advanced pancreatic cancer in combination with gemcitabine and nab-paclitaxel, based on PANOVA-3 which showed longer median overall survival and pain-free survival with TTFields versus chemotherapy alone; skin reactions were common; the device costs about $21,000 per month and includes patches, a generator, and support services.
- FDA Approves Wearable Device to Treat Pancreatic Cancer Medscape
- Michael Chuong: Humbled to be The First in the U.S. to Prescribe Optune Pax for Pancreatic Cancer Oncodaily
- Novocure Gets FDA Approval for Pancreatic Cancer Treatment; Shares Soar The Wall Street Journal
- New FDA-approved device to help patients battling pancreatic cancer News12 | Long Island
- Novocure’s stock rises 37% on FDA clearance of pancreatic cancer treatment device Yahoo Finance
Reading Insights
Total Reads
1
Unique Readers
1
Time Saved
2 min
vs 3 min read
Condensed
88%
512 → 62 words
Want the full story? Read the original article
Read on Medscape